{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"122.0","upperLimit":"NA","value":"227.0"},{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"486.0","upperLimit":"NA","value":"578.0"},{"comment":"The median and upper bound of the 95% confidence interval were not reached due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"328.0","upperLimit":"NA","value":"NA"},{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG003","lowerLimit":"32.0","upperLimit":"NA","value":"168.5"},{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG004","lowerLimit":"49.0","upperLimit":"NA","value":"496.0"},{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG005","lowerLimit":"315.0","upperLimit":"NA","value":"801.0"},{"comment":"The median and upper bound of the 95% confidence interval were not reached due to insufficient number of participants with events.","groupId":"OG006","lowerLimit":"106.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"8"}],"units":"Participants"}],"description":"Interval of time from date of first study drug treatment to date of death, for any reason (patients without documentation of death at the time of analysis were censored at the date the patient was last known to be alive)","dispersionType":"95% Confidence Interval","groups":[{"description":"VRx-3996: 10 mg twice daily (BID) valganciclovir: 900 mg BID","id":"OG000","title":"Phase 1b Dose Escalation Cohort 1"},{"description":"VRx-3996: 5 mg BID valganciclovir: 450 mg BID","id":"OG001","title":"Phase 1b Dose Escalation Cohort 2a"},{"description":"VRx-3996: 10 mg once daily (QD) valganciclovir: 450 mg BID","id":"OG002","title":"Phase 1b Dose Escalation Cohort 2b"},{"description":"VRx-3996: 10 mg QD valganciclovir: 900 mg QD","id":"OG003","title":"Phase 1b Dose Escalation Cohort 2c"},{"description":"VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD","id":"OG004","title":"Phase 1b Dose Escalation Cohort 3"},{"description":"VRx-3996 (RP2D: 20 mg QD on Days 1 to 4/week) and valganciclovir (RP2D: 900 mg QD)","id":"OG005","title":"Phase 2 Expansion - Capsule"},{"description":"VRx-3996 (RP2D: 20 mg QD on Days 1 to 4/week) and valganciclovir (RP2D: 900 mg QD)","id":"OG006","title":"Phase 2 Expansion - Tablet"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Analysis Set, defined as all patients with measurable/evaluable disease at screening who met all eligibility criteria and had at least one evaluable post-baseline efficacy tumor assessment. Valganciclovir dosage reductions were allowed for participants with renal impairment at study entry or during study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"days"}